BRPI0923199B8 - método para determinar a presença de anticorpos de fixação de complemento - Google Patents

método para determinar a presença de anticorpos de fixação de complemento

Info

Publication number
BRPI0923199B8
BRPI0923199B8 BRPI0923199A BRPI0923199A BRPI0923199B8 BR PI0923199 B8 BRPI0923199 B8 BR PI0923199B8 BR PI0923199 A BRPI0923199 A BR PI0923199A BR PI0923199 A BRPI0923199 A BR PI0923199A BR PI0923199 B8 BRPI0923199 B8 BR PI0923199B8
Authority
BR
Brazil
Prior art keywords
complement
complement factor
factor
exogenous human
autologous
Prior art date
Application number
BRPI0923199A
Other languages
English (en)
Inventor
B Tyan Dolly
Chen Ge
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of BRPI0923199A2 publication Critical patent/BRPI0923199A2/pt
Publication of BRPI0923199B1 publication Critical patent/BRPI0923199B1/pt
Publication of BRPI0923199B8 publication Critical patent/BRPI0923199B8/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4716Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants

Abstract

métodos e composições para detecção de anticorpos com fixação de complemento. a invenção fornece métodos para detecção sensível e específica de anticorpos com fixação de complemento em uma amostra biológica usando o fator de complemento c1q, incluindo fator de complemento autólogo c1q presente na amostra biológica e um anticorpo marcado de forma detectável que se liga ao fator de complemento autólogo c1q, fator de complexo exógeno humano c1q e um anticorpo marcado de forma detectável que se liga ao fator de complemento humano exógeno c1q, fator de complemento humano exógeno c1q marcado de forma detectável, ou uma combinação de fator de complemento autólogo c1q e fator de complemento humano exógeno c1q. a invenção também apresenta kits, sistemas e dispositivos para uso nos métodos da invenção.
BRPI0923199A 2008-12-01 2009-11-25 método para determinar a presença de anticorpos de fixação de complemento BRPI0923199B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11894908P 2008-12-01 2008-12-01
US61/118,949 2008-12-01
PCT/US2009/065984 WO2010065425A1 (en) 2008-12-01 2009-11-25 Methods and compositions for detection of complement fixing antibodies

Publications (3)

Publication Number Publication Date
BRPI0923199A2 BRPI0923199A2 (pt) 2016-02-16
BRPI0923199B1 BRPI0923199B1 (pt) 2020-10-20
BRPI0923199B8 true BRPI0923199B8 (pt) 2021-07-27

Family

ID=42233567

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923199A BRPI0923199B8 (pt) 2008-12-01 2009-11-25 método para determinar a presença de anticorpos de fixação de complemento

Country Status (8)

Country Link
US (1) US10338080B2 (pt)
EP (2) EP3460480B1 (pt)
JP (2) JP5792626B2 (pt)
CN (2) CN105866426B (pt)
AU (1) AU2009322607B2 (pt)
BR (1) BRPI0923199B8 (pt)
CA (1) CA2740192C (pt)
WO (1) WO2010065425A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3722320A3 (en) * 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
JP6543572B2 (ja) 2012-11-02 2019-07-10 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体C1s抗体とそれらの用途
US20160041185A1 (en) * 2013-03-14 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Methods of Detecting Complement Fixing and Non-Complement Fixing Antibodies and Systems for Practicing the Same
CA2905954C (en) * 2013-03-14 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting donor-specific antibodies and systems for practicing the same
JP6462680B2 (ja) 2013-07-09 2019-01-30 アネクソン,インコーポレーテッド 抗補体因子C1q抗体及びその使用
KR102626877B1 (ko) * 2014-11-05 2024-01-19 애넥슨, 인코포레이티드 인간화 항-보체 인자 c1q 항체 및 이의 용도
RS63956B1 (sr) 2015-04-06 2023-02-28 Bioverativ Usa Inc Humanizovana anti-c1s antitela i metode njihove upotrebe
US10527613B2 (en) 2015-11-10 2020-01-07 The Board Of Trustees Of The Leland Stanford Junior University Biomarker detection methods and systems and kits for practicing same
CA3010587C (en) 2015-12-03 2021-08-17 NJ Sharing Network Igg subtyping assay for identifying transplantable tissue samples
WO2017187656A1 (ja) * 2016-04-27 2017-11-02 株式会社Jimro 抗医薬品抗体の測定方法
EP3239711B1 (en) * 2016-04-27 2019-12-25 JIMRO Co., Ltd. Method for measuring anti-drug antibody
WO2018140655A2 (en) * 2017-01-25 2018-08-02 Northeastern University Electrochemical antibody-based biosensor
CN111398580B (zh) * 2017-11-03 2023-06-13 科美诊断技术股份有限公司 一种检测样本中目标IgM抗体的方法
CN109991405B (zh) * 2017-12-29 2023-01-24 上海索昕生物科技有限公司 一种免疫检测试剂盒及其应用
JP7153494B2 (ja) * 2018-07-27 2022-10-14 シスメックス株式会社 生体粒子の測定方法、非特異シグナルの検出方法、生体粒子測定方法及び生体粒子を検出するための試薬キット
AU2020270071A1 (en) * 2019-05-06 2021-10-21 The Regents Of The University Of California Non-HLA markers of transplant rejection
CN111812336A (zh) * 2020-08-10 2020-10-23 苏州康和顺医疗技术有限公司 用于检测冠状病毒抗体的检测试剂盒及其制备方法
EP4226155A1 (en) * 2020-10-09 2023-08-16 Takeda Vaccines, Inc. Methods for determining complement-fixing antibodies
WO2022212704A1 (en) * 2021-03-31 2022-10-06 Takeda Vaccines, Inc. Methods for characterizing the immune response of a subject to a dengue virus composition
EP4089413A1 (en) * 2021-05-12 2022-11-16 Cisbio Bioassays Method for determining the binding of an antibody to the complement component 1q (c1q)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5035995A (en) * 1984-10-02 1991-07-30 Calpis Food Industry Co., Ltd. Test method involving substance-conjugated complement component C1q
JPS6184560A (ja) * 1984-10-02 1986-04-30 Karupisu Shokuhin Kogyo Kk 補体結合性抗体の測定法
JPS61245060A (ja) 1985-04-23 1986-10-31 Takara Shuzo Co Ltd ヒト補体1q定量用キツト及び定量法
JPS6225994A (ja) * 1985-05-30 1987-02-03 ジエネテイツク システムズ コ−ポレイシヨン Hlaタイプ分け用モノクロ−ナル抗体
IL84160A0 (en) 1986-10-16 1988-03-31 Vasocor Method and kit for immune complex assay
US5176998A (en) 1986-12-01 1993-01-05 The Scripps Research Institute Cell surface antigen detection method
US5223397A (en) 1991-06-05 1993-06-29 Sangstat Medical Corporation Soluble hla cross-match
US5270169A (en) * 1992-06-23 1993-12-14 Sangstat Medical Corporation Detection of HLA antigen-containing immune complexes
DE69334095T2 (de) 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
US5851829A (en) 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
GB9502112D0 (en) 1995-02-03 1995-03-22 British Biocell Int Assay device and method
US6159748A (en) * 1995-03-13 2000-12-12 Affinitech, Ltd Evaluation of autoimmune diseases using a multiple parameter latex bead suspension and flow cytometry
US5948627A (en) * 1997-05-30 1999-09-07 One Lambda Immunobead flow cytometric detection of anti-HLA panel-reactive antibody
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
CN1423130A (zh) * 2002-04-26 2003-06-11 帕弗瑞生物技术(北京)有限公司 流式测定固定补体抗体的hla交叉配型方法和试剂盒
CN1444044A (zh) * 2002-06-18 2003-09-24 帕弗瑞生物技术(北京)有限公司 以酶联免疫测定为基础的hla补体依赖性细胞毒性抗体检测方法和试剂盒
TW200508609A (en) 2003-07-15 2005-03-01 Bioarray Solutions Ltd Detection of cell membrane-associated proteins using membrane fragments displayed on encoded microparticle arrays
US20050277158A1 (en) * 2004-06-10 2005-12-15 Ge Chen Method and kit for donor specific complement-fixing antibodies crossmatch
US7799556B2 (en) * 2004-06-17 2010-09-21 George Dacai Liu System and method for antigen structure-independent detection of antigens captured on antibody arrays
EP1888781A4 (en) 2005-05-06 2009-01-21 Platypus Technologies Llc ANALYTIC DETECTION ON LIQUID CRYSTAL BASIS
CN100354629C (zh) 2005-10-17 2007-12-12 中国人民解放军第三军医大学第一附属医院 用胶体金标记补体第一成分q亚单位做指示剂的蛋白芯片/微阵列检测系统及检测方法
GB0618496D0 (en) 2006-09-20 2006-11-01 Common Services Agency Blood typing
JP2008100986A (ja) 2006-09-21 2008-05-01 Takahiro Ochi C1q結合物質、ならびにその使用
US7964350B1 (en) 2007-05-18 2011-06-21 Applied Biosystems, Llc Sample preparation for in situ nucleic acid analysis
JP2009080019A (ja) 2007-09-26 2009-04-16 Nippon Sekijiyuujishiya 蛍光ビーズを用いた免疫複合体検出による抗体解析法
DE102008045696A1 (de) 2008-09-04 2010-03-11 Drk Blutspendedienst West Ggmbh Granulozyten HNA-3a/b-Antigen
CA2763199A1 (en) 2009-05-29 2010-12-02 The Regents Of The Univeristy Of California B cell signature associated with tolerance in transplant recipients
US20120065092A1 (en) 2010-09-14 2012-03-15 Wai Hobert Fusion analyte cytometric bead assay, and systems and kits for performing the same
AU2012304181C1 (en) 2011-08-30 2017-04-27 The Governors Of The University Of Alberta Method and system for ABO antibody detection and characterization
CA2905954C (en) 2013-03-14 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting donor-specific antibodies and systems for practicing the same
US20160041185A1 (en) 2013-03-14 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Methods of Detecting Complement Fixing and Non-Complement Fixing Antibodies and Systems for Practicing the Same

Also Published As

Publication number Publication date
CN105866426B (zh) 2018-11-23
BRPI0923199B1 (pt) 2020-10-20
CN102203610A (zh) 2011-09-28
AU2009322607B2 (en) 2015-05-14
US20110281757A1 (en) 2011-11-17
JP2015007651A (ja) 2015-01-15
EP2353005A4 (en) 2012-10-17
EP3460480B1 (en) 2022-11-02
JP5792626B2 (ja) 2015-10-14
CA2740192A1 (en) 2010-06-10
EP2353005B1 (en) 2018-10-03
BRPI0923199A2 (pt) 2016-02-16
JP2012510618A (ja) 2012-05-10
CA2740192C (en) 2019-12-31
WO2010065425A1 (en) 2010-06-10
CN105866426A (zh) 2016-08-17
AU2009322607A1 (en) 2010-06-10
EP3460480A1 (en) 2019-03-27
EP2353005A1 (en) 2011-08-10
US10338080B2 (en) 2019-07-02

Similar Documents

Publication Publication Date Title
BRPI0923199B8 (pt) método para determinar a presença de anticorpos de fixação de complemento
BRPI0906903B8 (pt) anticorpo monoclonal e método de detecção da expressão de cd70
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
CY1126069T1 (el) Προσδιορισμος για αντισωματα ιου jc
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
BR112015014833A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno deste, ácido nucléico isolado, célula hospedeira, método de ensaiar uma amostra de tecido removido de um humano para expressão de pd-l1, estojo, e, composição de anticorpo que compreende uma mistura de moléculas do anticorpo
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
EA201992748A1 (ru) Диагностические анализы для обнаружения, количественного определения и/или отслеживания микроорганизмов и других аналитов
WO2010065568A3 (en) METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
BR112015023239A2 (pt) ensaio de combinação antígeno-anticorpo e métodos e composições para uso do mesmo
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
BR112016010106A2 (pt) ensaios para igfbp7 com melhor desempenho em amostras biológicas
BR112013026580A2 (pt) método para quantificar múltiplas imunoglobulinas específicas de antígeno e para calibrar um dispositivo adequado, sistema de teste multialergeno, e, kit de partes
WO2008070865A3 (en) Materials and methods for efficient and accurate detection of analytes
BR112017021686A2 (pt) método para detectar uma ou várias carbapenemases, dispositivo para detectar imunocromatográfico e uso do dispositivo para detectar imunocromatográfico
BR112012009846A2 (pt) ensaios para detecção de anticorpos específicos para anticorpos anti-ige terapêuticos e seu uso em anafilaxia
BR112012019475A2 (pt) "uso de um anticorpo monoclonal anti-cd 44 anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
AR068043A1 (es) Uso de glicosaminoglicanos para reducir la union inespecifica en inmunoensayos
BR112015022844A8 (pt) método para determinar a presença ou ausência de anticorpos específicos do doador em uma amostra biológica, sistema e kit para praticar o mesmo
WO2010046443A3 (en) Methods for detection and diagnosis of a bone or cartilage disorder
BR112016007037A2 (pt) método para detectar câncer pancreático, anticorpo monoclonal e kit
AR103935A1 (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2
MX2020009278A (es) Ensayos para detectar la neurodegeneración.
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO